Cargando…
Therapy-related MDS dissected based on primary disease and treatment—a nationwide perspective
In this population-based study, we aimed to characterize and compare subgroups of therapy-related Myelodysplastic syndromes (t-MDS) and define the implications of type of previous treatment and primary disease. We combined data from MDS patients, diagnosed between 2009 and 2017 (n = 2705), in the na...
Autores principales: | Moreno Berggren, Daniel, Garelius, Hege, Willner Hjelm, Petter, Nilsson, Lars, Rasmussen, Bengt, Weibull, Caroline E., Lambe, Mats, Lehmann, Sören, Hellström-Lindberg, Eva, Jädersten, Martin, Ejerblad, Elisabeth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169633/ https://www.ncbi.nlm.nih.gov/pubmed/36928008 http://dx.doi.org/10.1038/s41375-023-01864-6 |
Ejemplares similares
-
“Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”
por: Rasmussen, Bengt, et al.
Publicado: (2022) -
P506: CLINICAL VALIDATION OF THE NORDIC GUIDELINES FOR GERMLINE TESTING IN MYELOID NEOPLASMS: RESULTS FROM A MULTI-CENTER PROSPECTIVE COHORT STUDY
por: Tesi, Bianca, et al.
Publicado: (2023) -
The extent of residual WT HSPCs is associated with the degree of anemia in patients with SF3B1-mutated MDS-RS
por: Hofman, Isabel Juliana F., et al.
Publicado: (2022) -
Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
por: de Witte, Theo, et al.
Publicado: (2020) -
Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease
por: Tobiasson, Magnus, et al.
Publicado: (2017)